ADVM
Adverum Biotechnologies, Inc.
Set alert
52-week range unavailable
- YTD
- -6.64%
- 1 year
- -26.23%
- Open
- 4.24
- Prev close
- 4.36
- Mkt cap
- 98.60M
- Vol
- 675.98K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 4.24
- High
- 4.36
- Forward P/E
- -0.89
- Beta
- 1.01
- Short ratio
- 5.53
- Inst. own
- 79.11%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 6.82
- 200-d avg
- 8.42
- 1y target
- 29.71
Key statistics
- Market cap
- 98.60M
- Enterprise value
- 18.63M
- Trailing P/E
- 0.00
- Forward P/E
- -0.89
- PEG ratio
- 0.00
- Price / sales
- 98.60
- Price / book
- 0.68
- EPS (TTM)
- -5.95
- Beta
- 1.01
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 1.00M
- Revenue growth
- 0.00%
- Free cash flow
- -47.60M
- Total cash
- 153.24M
- Total debt
- 73.26M
- Return on equity
- -76.26%
- Shares outstanding
- 20.80M
- Short % of float
- 6.57%
- 50-day average
- 6.82
- 200-day average
- 8.42
Analyst view
Consensus: none
- Target (low)
- 10.00
- Target (mean)
- 29.71
- Target (high)
- 40.00
- Strong buy1
- Buy6
- Hold1
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -1.39.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2024 | Sep 1, 2024 | -1.20 | -1.30 | -0.10 | -8.33% |
| Aug 12, 2024 | Jun 1, 2024 | -1.27 | -0.89 | +0.38 | +29.92% |
| May 9, 2024 | Mar 1, 2024 | -1.28 | -1.50 | -0.22 | -17.19% |
| Mar 18, 2024 | Dec 1, 2023 | -2.80 | -2.30 | +0.50 | +17.86% |
| Nov 9, 2023 | Sep 1, 2023 | -3.00 | -3.30 | -0.30 | -10.00% |
| Aug 10, 2023 | Jun 1, 2023 | -3.20 | -3.10 | +0.10 | +3.13% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 19, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 5, 2024 | RBC Capital | main | Sector Perform | Sector Perform |
| Aug 14, 2024 | Truist Securities | main | Buy | Buy |
| Aug 13, 2024 | HC Wainwright& Co. | reit | Buy | Buy |
| Aug 13, 2024 | RBC Capital | main | Sector Perform | Sector Perform |
| Jul 18, 2024 | Chardan Capital | main | Buy | Buy |
About Adverum Biotechnologies, Inc.
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- adverum.com
News
- Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Receives $10.50 Consensus Target Price from Analysts
- First Look: Fed Cut Looms; SpaceX IPO; J&J Myeloma Data; Google Probe
- Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition
- Adverum Reminds Stockholders to Tender their Shares into the Offer by Lilly
- Halper Sadeh LLC Encourages BRNS, FITB, ADVM, HBAN Shareholders to Contact the Firm to Discuss Their Rights
- This Alto Neuroscience Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
- Adverum Biotechnologies (ADVM) Projected to Post Quarterly Earnings on Monday
- ADVM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Adverum Biotechnologies, Inc. Is Fair to Shareholders
- Adverum Biotechnologies Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Adverum Biotechnologies, Inc. - ADVM
- $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Adverum Biotechnologies, Inc. (NASDAQ: ADVM)
Your note
Sign in to keep a note on ADVM — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| FISCHER LAURENT D M.D. | Chief Executive Officer | Sale | Mar 14, 2023 | 692,141 |
| LEONARD BRADEN MICHAEL | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jul 29, 2024 | 0 |
| LUPHER MARK L. JR., PH.D. | Director | Purchase | Feb 6, 2024 | 0 |
| RILEY BRIGIT | Officer | Sale | Mar 14, 2023 | 117,435 |
| RUBINSTEIN LINDA M. | Chief Financial Officer | Purchase | Jun 6, 2023 | 100,000 |
| SCOPA JAMES PAUL | Director | Purchase | Feb 6, 2024 | 103,334 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| BML Capital Management, LLC | 10.90% | 2,268,064 | 10.75M | Sep 29, 2024 |
| TCG Crossover Management, LLC | 9.65% | 2,008,339 | 9.52M | Sep 29, 2024 |
| Franklin Resources, Inc. | 8.46% | 1,760,056 | 8.34M | Sep 29, 2024 |
| Blackrock Inc. | 7.17% | 1,490,709 | 7.07M | Sep 29, 2024 |
| VR Adviser, LLC | 7.05% | 1,467,048 | 6.95M | Sep 29, 2024 |
| Frazier Life Sciences Management, L.P. | 5.14% | 1,069,244 | 5.07M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Franklin Strategic Series-Franklin Biotechnology Discove | 3.00% | 624,737 | 2.96M | Jul 30, 2024 |
| Vanguard Total Stock Market Index Fund | 2.82% | 586,245 | 2.78M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.61% | 543,653 | 2.58M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.37% | 285,796 | 1.35M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 1.02% | 211,580 | 1.00M | Aug 30, 2024 |
| iShares Russell 2000 Value ETF | 0.93% | 192,615 | 913.00K | Oct 30, 2024 |